Solos Endoscopy, Inc. Reports a 9% Increase in Sales for the 4th Quarter 2009 as Compared to 4th Quarter 2008

Jan 22, 2010, 08:31 ET from Solos Endoscopy, Inc.

BOSTON, Jan. 22 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce the Company has generated $125,791 in sales transactions for the fourth quarter of 2009 versus $115,159 in sales transactions that Solos generated for the fourth quarter of 2008, which is a 9 percent increase.

"This is a positive way for Solos to end 2009. Our sales numbers remained relatively consistent throughout 2009 as compared to 2008 despite the difficult economic climate. We are optimistic that the fourth quarter results are representative of a continued positive trend for 2010," stated Bob Segersten, President of Solos Endoscopy, Inc.

Solos Endoscopy generates its revenues through the sale of its extensive line of medical instruments, which include imaging systems, hand held surgical instruments and endoscopic equipment. The Company's unaudited 4th quarter financial statements, along with 2009 year-end financials, will soon be available to view on the Pink Sheets at

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at:

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

SOURCE Solos Endoscopy, Inc.